共 50 条
Invasive community-associated MRSA infections: epidemiology and antimicrobial management
被引:21
|作者:
Pichereau, Solen
[1
,2
,3
]
Rose, Warren E.
[1
]
机构:
[1] Univ Madison, Sch Pharm, Pharm Practice Div, Madison, WI 53705 USA
[2] INSERM, ERI 23, F-75654 Paris 13, France
[3] Univ Poitiers, Poitiers, France
关键词:
CA-MRSA;
epidemiology;
resistance;
Staphylococcus aureus;
treatment;
RESISTANT STAPHYLOCOCCUS-AUREUS;
SKIN-STRUCTURE INFECTIONS;
SOFT-TISSUE INFECTIONS;
BLOOD-STREAM INFECTIONS;
IN-VITRO ACTIVITY;
INDUCIBLE CLINDAMYCIN RESISTANCE;
VENTILATOR-ASSOCIATED PNEUMONIA;
GRAM-POSITIVE COCCI;
DOUBLE-BLIND;
METHICILLIN-RESISTANT;
D O I:
10.1517/14656566.2010.511614
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Importance of the field: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is now a predominant cause of infections in the community and is adding to the overwhelming MRSA burden in the hospital setting. CA-MRSA is most commonly noted as a prominent pathogen in skin and soft tissue infections (SSTI) but has been increasingly described in more invasive disease. New developments in the epidemiology and treatment of CA-MRSA have emerged to improve the understanding of this disease. Areas covered in this review: We present the latest epidemiologic and clinical treatment studies of CA-MRSA in a variety of infection types. The methods used involve a comprehensive literature search of the previous 10 years, including a detailed focus on new literature in the last 5 years. The search terms used were 'CA-MRSA epidemiology', 'S. aureus resistance', 'CA-MRSA treatment', and 'S. aureus virulence'. What the reader will gain: An in-depth understanding of the changing epidemiology of CA-MRSA and management of SSTI and more invasive infections with this pathogen. Adjunctive and alternative therapies are also reviewed. Take home message: The epidemiology of CA-MRSA is rapidly evolving. Increasing multi-drug resistance along with virulence factors associated with this serious disease complicate its treatment. Additional clinical trials are needed to select optimal regimens in the treatment of invasive CA-MRSA infections.
引用
收藏
页码:3009 / 3025
页数:17
相关论文